{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:32:23Z","timestamp":1787311943024,"version":"build-2736575974"},"reference-count":131,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Lysosomal Storage Diseases (LSDs) include roughly 70 inherited metabolic disorders, most of which are expressed in an autosomal recessive pattern. These conditions arise from mutations in genes encoding lysosomal enzymes, leading to intracellular buildup of substrates and subsequent lysosomal dysfunction. LSDs can be broadly classified based on the nature of the stored substrate, encompassing Sphingolipidoses, Mucopolysaccharidoses, Lysosomal Glycogen Storage Disease, Oligosaccharidoses, Mucolipidoses, and Lysosomal Proteinoses. Although individually rare, LSDs collectively affect approximately 1 in 5000 live births. They usually manifest in childhood, but adult-onset types are also detected. Clinical manifestations are heterogeneous and may involve the central nervous system, skeletal system, skin, heart, muscles, kidneys, and other organs. Several therapeutic strategies are available for LSDs, including Enzyme Replacement Therapy to restore deficient enzymes, Hematopoietic Stem Cell Transplantation to provide functional donor-derived cells, Substrate Reduction Therapy and pharmacological chaperones to modulate substrate turnover or enhance enzyme stability, alongside symptomatic and supportive treatments. Ongoing research is also exploring gene therapy-based strategies. Current diagnostic criteria remain insufficient for reliable presymptomatic diagnosis, highlighting the need for more sensitive and specific approaches. In this context, untargeted metabolomics is a powerful strategy to investigate pathogenic pathways, identify novel diagnostic and prognostic biomarkers, and uncover potential therapeutic targets. Accordingly, this review provides an overview of LSDs, focusing on untargeted metabolomics studies and their contribution to the discovery of novel biomarkers and previously unrecognised pathogenic mechanisms relevant to diagnostic and therapeutic innovation.<\/jats:p>","DOI":"10.3390\/metabo16070480","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:27:31Z","timestamp":1783531651000},"page":"480","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolomic Insights into Lysosomal Storage Diseases: An Untargeted View"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6910-2391","authenticated-orcid":false,"given":"Gessica","family":"Di Carlo","sequence":"first","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Department of Science, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2721-2593","authenticated-orcid":false,"given":"Maria Lucia","family":"Tommolini","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Department of Innovative Technologies in Medicine and Dentistry, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Frisco","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Department of Human, Legal and Economic Sciences, Telematic University of \u201cLeonardo Da Vinci\u201d, 66010 Torrevecchia Teatina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0354-6844","authenticated-orcid":false,"given":"Giorgia","family":"Spalluto","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Department of Neuroscience, Imaging and Clinical Sciences, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Foley","sequence":"additional","affiliation":[{"name":"Department of Science, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-5627","authenticated-orcid":false,"given":"Mirco","family":"Zucchelli","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Department of Innovative Technologies in Medicine and Dentistry, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6457-7795","authenticated-orcid":false,"given":"Maria Concetta","family":"Cufaro","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Department of Innovative Technologies in Medicine and Dentistry, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9792-2225","authenticated-orcid":false,"given":"Ilaria","family":"Cicalini","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6806-7127","authenticated-orcid":false,"given":"Ines","family":"Bucci","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Department of Medicine and Aging Science, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Federici","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Department of Innovative Technologies in Medicine and Dentistry, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"De Laurenzi","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Department of Innovative Technologies in Medicine and Dentistry, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-3484","authenticated-orcid":false,"given":"Damiana","family":"Pieragostino","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Department of Innovative Technologies in Medicine and Dentistry, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0949-0280","authenticated-orcid":false,"given":"Claudia","family":"Rossi","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Department of Science, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/B978-0-323-99209-1.00008-9","article-title":"Lysosomal Storage Diseases","volume":"204","author":"Burlina","year":"2024","journal-title":"Handb. Clin. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ismail, I.T., Showalter, M.R., and Fiehn, O. (2019). Inborn Errors of Metabolism in the Era of Untargeted Metabolomics and Lipidomics. Metabolites, 9.","DOI":"10.3390\/metabo9100242"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Santos, R., and Amaral, O. (2019). Advances in Sphingolipidoses: CRISPR-Cas9 Editing as an Option for Modelling and Therapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20235897"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Martineau, T., Maranda, B., and Auray-Blais, C. (2024). UPLC-MS\/MS High-Risk Screening for Sphingolipidoses Using Dried Urine Spots. Biomolecules, 14.","DOI":"10.3390\/biom14121612"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2024069152","DOI":"10.1542\/peds.2024-069152","article-title":"Evidence and Recommendation for Infantile Krabbe Disease Newborn Screening","volume":"155","author":"Ream","year":"2025","journal-title":"Pediatrics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/gim.2015.211","article-title":"Newborn Screening for Krabbe Disease in New York State: The First Eight Years\u2019 Experience","volume":"18","author":"Orsini","year":"2016","journal-title":"Genet. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/jnr.23847","article-title":"Hematopoietic Stem Cell Transplantation and Lentiviral Vector-Based Gene Therapy for Krabbe\u2019s Disease: Present Convictions and Future Prospects","volume":"94","author":"Hu","year":"2016","journal-title":"J. Neurosci. Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Alabed, H.B.R., Del Grosso, A., Bellani, V., Urbanelli, L., Carpi, S., De Sarlo, M., Bertocci, L., Colagiorgio, L., Buratta, S., and Scaccini, L. (2023). Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease. Biomolecules, 13.","DOI":"10.3390\/biom13101562"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Matern, D., Basheeruddin, K., Klug, T.L., McKee, G., Edge, P.U., Hall, P.L., Kurtzberg, J., and Orsini, J.J. (2024). Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10010010"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/s41436-020-0764-y","article-title":"The Critical Role of Psychosine in Screening, Diagnosis, and Monitoring of Krabbe Disease","volume":"22","author":"Guenzel","year":"2020","journal-title":"Genet. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/jnr.23789","article-title":"Metabolic Profiling Reveals Biochemical Pathways and Potential Biomarkers Associated with the Pathogenesis of Krabbe Disease","volume":"94","author":"Weinstock","year":"2016","journal-title":"J. Neurosci. Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Rodrigues, K.F., Yong, W.T.L., Bhuiyan, M.S.A., Siddiquee, S., Shah, M.D., and Venmathi Maran, B.A. (2022). Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review. Biology, 11.","DOI":"10.3390\/biology11091308"},{"key":"ref_13","first-page":"e1121","article-title":"From red flags to diagnosis: A hepatologist\u2019s guide to Gaucher disease and acid sphingomyelinase deficiency in adults\u2014insights from the Italian \u201cCloser to Care\u201d initiative","volume":"3","author":"Nascimbeni","year":"2026","journal-title":"J. Innate Metab."},{"key":"ref_14","first-page":"e1123","article-title":"Bone Complications in Gaucher Disease: A Narrative Review","volume":"3","author":"Belinazzi","year":"2026","journal-title":"J. Innate Metab."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Breuer, M., and Patten, S.A. (2020). A Great Catch for Investigating Inborn Errors of Metabolism-Insights Obtained from Zebrafish. Biomolecules, 10.","DOI":"10.3390\/biom10091352"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gelb, M.H. (2018). Newborn Screening for Lysosomal Storage Diseases: Methodologies, Screen Positive Rates, Normalization of Datasets, Second-Tier Tests, and Post-Analysis Tools. Int. J. Neonatal Screen., 4.","DOI":"10.3390\/ijns4030023"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rossi, C., Ferrante, R., Valentinuzzi, S., Zucchelli, M., Buccolini, C., Di Rado, S., Trotta, D., Stuppia, L., Federici, L., and Aric\u00f2, M. (2023). Noninvasive DBS-Based Approaches to Assist Clinical Diagnosis and Treatment Monitoring of Gaucher Disease. Biomedicines, 11.","DOI":"10.3390\/biomedicines11102672"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rossi, C., Trotta, D., Ferrante, R., Pieragostino, D., Valentinuzzi, S., Federici, L., Stuppia, L., De Laurenzi, V., and Aric\u00f2, M. (2025). Prospective Monitoring of Lyso-Gb1 on DBS Sample in Three Children Recognized at Newborn Screening for Gaucher Disease and Untreated. Children, 12.","DOI":"10.3390\/children12030350"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Menkovic, I., Boutin, M., Alayoubi, A., Mercier, F.E., Rivard, G.-\u00c9., and Auray-Blais, C. (2020). Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217869"},{"key":"ref_20","first-page":"e537","article-title":"Supportive Care in Adults with Fabry Disease: Low-Cost Interventions for High-Value Achievements","volume":"1","author":"Chesini","year":"2024","journal-title":"J. Innate Metab."},{"key":"ref_21","first-page":"e998","article-title":"Exploring Neuropathic Pain in Fabry Disease: A Review of Pathogenesis, Diagnostic Pitfalls and Management Starting from Clinical Cases","volume":"2","author":"Cappozzo","year":"2025","journal-title":"J. Innate Metab."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Levstek, T., Vujkovac, B., and Trebusak Podkrajsek, K. (2020). Biomarkers of Fabry Nephropathy: Review and Future Perspective. Genes, 11.","DOI":"10.3390\/genes11091091"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rocchetti, M.T., Spadaccino, F., Catalano, V., Zaza, G., Stallone, G., Fiocco, D., Netti, G.S., and Ranieri, E. (2022). Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects. Metabolites, 12.","DOI":"10.3390\/metabo12080703"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tuttolomondo, A., Baglio, I., Riolo, R., Todaro, F., Parrinello, G., Miceli, S., and Simonetta, I. (2023). Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202308.1540.v1"},{"key":"ref_25","first-page":"e593","article-title":"Therapeutic Approach to Pediatric Patients with Classic Fabry Disease: Towards a New Paradigm","volume":"1","author":"Spada","year":"2024","journal-title":"J. Innate Metab."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Simonetta, I., Tuttolomondo, A., Daidone, M., and Pinto, A. (2020). Biomarkers in Anderson-Fabry Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218080"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e213817","DOI":"10.1212\/WNL.0000000000213817","article-title":"Metachromatic Leukodystrophy: New Therapy Advancements and Emerging Research Directions","volume":"105","author":"Asbreuk","year":"2025","journal-title":"Neurology"},{"key":"ref_28","first-page":"168","article-title":"Identification of Neurodegeneration Indicators and Disease Progression in Metachromatic Leukodystrophy Using Quantitative NMR-Based Urinary Metabolomics","volume":"63","author":"Laugwitz","year":"2022","journal-title":"JIMD Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12944-022-01644-8","article-title":"Lipidomic Analysis Identifies Age-Disease-Related Changes and Potential New Biomarkers in Brain-Derived Extracellular Vesicles from Metachromatic Leukodystrophy Mice","volume":"21","author":"Pergande","year":"2022","journal-title":"Lipids Health Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Malvagia, S., Bettiol, A., Porcaro, M., Mura, M., Funghini, S., Ombrone, D., Forni, G., Scolamiero, E., Coppi, F., and Damiano, R. (2025). Newborn Screening for Metachromatic Leukodystrophy in Tuscany: The Paradigm of a Successful Preventive Medicine Program. Int. J. Neonatal Screen., 11.","DOI":"10.3390\/ijns11020030"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"108436","DOI":"10.1016\/j.ymgme.2024.108436","article-title":"Higher Precision, First Tier Newborn Screening for Metachromatic Leukodystrophy Using 16:1-OH-Sulfatide","volume":"142","author":"Bekri","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Percival, B.C., Latour, Y.L., Tifft, C.J., and Grootveld, M. (2021). Rapid Identification of New Biomarkers for the Classification of GM1 Type 2 Gangliosidosis Using an Unbiased 1H NMR-Linked Metabolomics Strategy. Cells, 10.","DOI":"10.3390\/cells10030572"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ymgme.2014.11.015","article-title":"Biomarkers of Central Nervous System Inflammation in Infantile and Juvenile Gangliosidoses","volume":"114","author":"Utz","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymgme.2018.09.005","article-title":"Metabolomics Profiling Reveals Profound Metabolic Impairments in Mice and Patients with Sandhoff Disease","volume":"126","author":"Ou","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lecommandeur, E., Cach\u00f3n-Gonz\u00e1lez, M.B., Boddie, S., McNally, B.D., Nicholls, A.W., Cox, T.M., and Griffin, J.L. (2020). Decrease in Myelin-Associated Lipids Precedes Neuronal Loss and Glial Activation in the CNS of the Sandhoff Mouse as Determined by Metabolomics. Metabolites, 11.","DOI":"10.3390\/metabo11010018"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12944-025-02675-7","article-title":"Advances in Mass Spectrometry of Lipids for the Investigation of Niemann-Pick Type C Disease","volume":"24","author":"Javanshad","year":"2025","journal-title":"Lipids Health Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1194\/jlr.M040618","article-title":"Identification of Niemann-Pick C1 Disease Biomarkers through Sphingolipid Profiling","volume":"54","author":"Fan","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100600","DOI":"10.1016\/j.jlr.2024.100600","article-title":"Accumulation of Alkyl-Lysophosphatidylcholines in Niemann-Pick Disease Type C1","volume":"65","author":"Mishra","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"337ra63","DOI":"10.1126\/scitranslmed.aaf2326","article-title":"Development of a Bile Acid-Based Newborn Screen for Niemann-Pick Disease Type C","volume":"8","author":"Jiang","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1038\/s41598-017-06264-2","article-title":"NMR Analysis Reveals Significant Differences in the Plasma Metabolic Profiles of Niemann Pick C1 Patients, Heterozygous Carriers, and Healthy Controls","volume":"7","author":"Probert","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Watanabe, M., Maekawa, M., Miyoshi, K., Sato, T., Sato, Y., Kumondai, M., Fukasawa, M., and Mano, N. (2024). Global and Targeted Metabolomics for Revealing Metabolomic Alteration in Niemann-Pick Disease Type C Model Cells. Metabolites, 14.","DOI":"10.3390\/metabo14100515"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Carmona, C.J., German-Morales, M., Elizondo, D., Ruiz-Rodado, V., and Grootveld, M. (2023). Urinary Metabolic Distinction of Niemann-Pick Class 1 Disease through the Use of Subgroup Discovery. Metabolites, 13.","DOI":"10.3390\/metabo13101079"},{"key":"ref_43","first-page":"e634","article-title":"Acid Sphingomyelinase Deficiency: A Complex and Rare Disorder That Needs Clinicians\u2019 Awareness","volume":"1","author":"Alagia","year":"2024","journal-title":"J. Innate Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13023-023-02686-6","article-title":"Consensus Clinical Management Guidelines for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease Types A, B and A\/B)","volume":"18","author":"Geberhiwot","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2018.11.014","article-title":"Recommendations for Clinical Monitoring of Patients with Acid Sphingomyelinase Deficiency (ASMD)","volume":"126","author":"Wasserstein","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e70039","DOI":"10.1002\/jimd.70039","article-title":"Exploring Exhaled Breath Analysis in Adults with Chronic Visceral Acid Sphingomyelinase Deficiency to Identify Potential Biomarkers of Pulmonary Involvement","volume":"48","author":"Eskes","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.accb.2019.09.001","article-title":"Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical and Biochemical Aspects of the Disease and Approaches to Its Diagnosis and Treatment","volume":"77","author":"Mohamed","year":"2020","journal-title":"Adv. Carbohydr. Chem. Biochem."},{"key":"ref_48","first-page":"100455","article-title":"Biomarkers in Patients with Mucopolysaccharidosis Type II and IV","volume":"19","author":"Fujitsuka","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"117250","DOI":"10.1016\/j.cca.2023.117250","article-title":"Untargeted LC-HRMS Metabolomics Reveals Candidate Biomarkers for Mucopolysaccharidoses","volume":"541","author":"Torres","year":"2023","journal-title":"Clin. Chim. Acta"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1038\/s41598-018-22078-2","article-title":"Fast, Sensitive Method for Trisaccharide Biomarker Detection in Mucopolysaccharidosis Type 1","volume":"8","author":"Makino","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ymgme.2019.09.001","article-title":"Evaluation of Non-Reducing End Pathologic Glycosaminoglycan Detection Method for Monitoring Therapeutic Response to Enzyme Replacement Therapy in Human Mucopolysaccharidosis I","volume":"129","author":"Vera","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"109231","DOI":"10.1016\/j.ymgme.2025.109231","article-title":"Defining Lung Pathogenesis in a Murine Model of Mucopolysaccharidosis Type I by Proteomic Analysis","volume":"146","author":"Ngai","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11306-025-02233-3","article-title":"Identification of Gangliosides and Ceramides as Biomarkers for Mucopolysaccharidosis Type II (Hunter Syndrome) through Untargeted Lipidomic Analysis","volume":"21","author":"Farjallah","year":"2025","journal-title":"Metabolomics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"109022","DOI":"10.1016\/j.ymgme.2025.109022","article-title":"Exploratory Metabolomic Profiling of Plasma and Urine in Patients with Mucopolysaccharidosis Type II (Hunter Syndrome): A Pilot Study","volume":"144","author":"Farjallah","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jnc.15891","article-title":"Biomarkers for Predicting Disease Course in Sanfilippo Syndrome: An Urgent Unmet Need in Childhood-onset Dementia","volume":"166","author":"Winner","year":"2023","journal-title":"J. Neurochem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12967-018-1625-1","article-title":"Unveiling Metabolic Remodeling in Mucopolysaccharidosis Type III through Integrative Metabolomics and Pathway Analysis","volume":"16","author":"Tebani","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Tebani, A., Abily-Donval, L., Schmitz-Afonso, I., Piraud, M., Ausseil, J., Zerimech, F., Pilon, C., Pereira, T., Marret, S., and Afonso, C. (2019). Analysis of Mucopolysaccharidosis Type VI through Integrative Functional Metabolomics. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020446"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2147\/TCRM.S351300","article-title":"Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)","volume":"18","author":"Poswar","year":"2022","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_59","first-page":"e541","article-title":"Selective Screening vs. Neonatal Screening in Infantile Onset Pompe Disease: A Case Series","volume":"1","author":"Gragnaniello","year":"2024","journal-title":"J. Innate Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15856","DOI":"10.18632\/aging.103794","article-title":"Pompe Disease: Pathogenesis, Molecular Genetics and Diagnosis","volume":"12","author":"Taverna","year":"2020","journal-title":"Aging"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Cebri\u00e1n, N., Gras-Colomer, E., Poveda Andr\u00e9s, J.L., Pineda-Lucena, A., and Puchades-Carrasco, L. (2023). Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes. Biology, 12.","DOI":"10.3390\/biology12091159"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.omtm.2020.05.026","article-title":"Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease","volume":"18","author":"Meena","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"109045","DOI":"10.1016\/j.ymgme.2025.109045","article-title":"Metabolic and Proteomic Profiles Provide Insights on Mechanism of Late Onset Pompe Disease","volume":"144","author":"Lu","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5966\/sctm.2015-0409","article-title":"Metabolomic Profiling of Pompe Disease-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals That Oxidative Stress Is Associated with Cardiac and Skeletal Muscle Pathology","volume":"6","author":"Sato","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1172-9-19","article-title":"Fast Urinary Screening of Oligosaccharidoses by MALDI-TOF\/TOF Mass Spectrometry","volume":"9","author":"Bonesso","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Mashima, R., Okuyama, T., and Ohira, M. (2020). Biomarkers for Lysosomal Storage Disorders with an Emphasis on Mass Spectrometry. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082704"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"108444","DOI":"10.1016\/j.ymgme.2024.108444","article-title":"Diagnosis of Alpha-Mannosidosis: Practical Approaches to Reducing Diagnostic Delays in This Ultra-Rare Disease","volume":"142","author":"Santoro","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e200317","DOI":"10.1212\/NXG.0000000000200317","article-title":"Expanding the Phenotype Spectrum of \u03b2-Mannosidosis","volume":"11","author":"Gibbs","year":"2025","journal-title":"Neurol. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Pekdemir, B., Bechelany, M., and Karav, S. (2025). Fucosidosis: A Review of a Rare Disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26010353"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Khan, A., and Sergi, C. (2018). Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder. Diagnostics, 8.","DOI":"10.3390\/diagnostics8020029"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/21678707.2016.1266933","article-title":"Galactosialidosis: Historic Aspects and Overview of Investigated and Emerging Treatment Options","volume":"5","author":"Annunziata","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-016-0544-6","article-title":"Aspartylglycosaminuria: A Review","volume":"11","author":"Arvio","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13023-016-0426-y","article-title":"Cystinosis: A Review","volume":"11","author":"Elmonem","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"501342","DOI":"10.1016\/j.nefro.2025.501342","article-title":"Phenotypic Variability in Cystinosis: Lessons from an Atypical Case","volume":"45","author":"Toso","year":"2025","journal-title":"Nefrologia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1681\/ASN.2014090937","article-title":"Cystinosin Is a Component of the Vacuolar H+-ATPase-Ragulator-Rag Complex Controlling Mammalian Target of Rapamycin Complex 1 Signaling","volume":"27","author":"Andrzejewska","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00467-010-1627-6","article-title":"Cystinosis: Practical Tools for Diagnosis and Treatment","volume":"26","author":"Wilmer","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100287","DOI":"10.1016\/j.labinv.2023.100287","article-title":"Omic Studies on In Vitro Cystinosis Model: SiRNA-Mediated CTNS Gene Silencing in HK-2 Cells","volume":"104","author":"Baysal","year":"2024","journal-title":"Lab. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"165498","DOI":"10.1016\/j.bbadis.2019.06.012","article-title":"Applying Modern Omic Technologies to the Neuronal Ceroid Lipofuscinoses","volume":"1866","author":"Kline","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","article-title":"Disease Characteristics and Progression in Patients with Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease: An Observational Cohort Study","volume":"2","author":"Nickel","year":"2018","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"15229","DOI":"10.1038\/s41598-018-33449-0","article-title":"Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease)","volume":"8","author":"Sindelar","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.bbadis.2013.05.014","article-title":"NCL Disease Mechanisms","volume":"1832","author":"Palmer","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbamcr.2008.11.004","article-title":"Neuronal Ceroid Lipofuscinoses","volume":"1793","author":"Jalanko","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"18550","DOI":"10.1038\/s41598-023-45789-7","article-title":"Neuronal Progenitor Cells-Based Metabolomics Study Reveals Dysregulated Lipid Metabolism and Identifies Putative Biomarkers for CLN6 Disease","volume":"13","author":"Rus","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/nan.12587","article-title":"Review: Danon Disease: Review of Natural History and Recent Advances","volume":"46","author":"Cenacchi","year":"2020","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e46993","DOI":"10.1097\/MD.0000000000046993","article-title":"Danon Disease: Two Case Reports and Literature Review","volume":"105","author":"Yu","year":"2026","journal-title":"Medicine"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Shalata, A., Bar-Shai, M., Hadid, Y., Mahroum, M., Mintz, H., Shalata, Z.E., Radzishevsky, E., Genizi, J., Lorber, A., and Ben-Yosef, T. (2023). Danon Disease: Entire LAMP2 Gene Deletion with Unusual Clinical Presentation-Case Report and Review of the Literature. Genes, 14.","DOI":"10.3390\/genes14081539"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Del Favero, G., Bonifacio, A., Rowland, T.J., Gao, S., Song, K., Sergo, V., Adler, E.D., Mestroni, L., Sbaizero, O., and Taylor, M.R.G. (2020). Danon Disease-Associated LAMP-2 Deficiency Drives Metabolic Signature Indicative of Mitochondrial Aging and Fibrosis in Cardiac Tissue and HiPSC-Derived Cardiomyocytes. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082457"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00018-024-05274-4","article-title":"Cellular Depletion of Major Cathepsin Proteases Reveals Their Concerted Activities for Lysosomal Proteolysis","volume":"81","author":"Gallwitz","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1515\/jpem-2025-0352","article-title":"Mucolipidosis Type II and III: Clinical Spectrum, Genetic Landscape, and Longitudinal Outcomes in a Pediatric Cohort with Six Novel Mutations","volume":"38","author":"Erdem","year":"2025","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s10038-020-0797-8","article-title":"Identification and Characterization of 30 Novel Pathogenic Variations in 69 Unrelated Indian Patients with Mucolipidosis Type II and Type III","volume":"65","author":"Pasumarthi","year":"2020","journal-title":"J. Hum. Genet."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1074\/jbc.M109.068650","article-title":"Functions of the Alpha, Beta, and Gamma Subunits of UDP-GlcNAc:Lysosomal Enzyme N-Acetylglucosamine-1-Phosphotransferase","volume":"285","author":"Qian","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Khan, S.A., and Tomatsu, S.C. (2020). Mucolipidoses Overview: Past, Present, and Future. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186812"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF00442708","article-title":"A Variant of Mucolipidosis. II. Clinical, Biochemical and Pathological Investigations","volume":"147","author":"Poenaru","year":"1988","journal-title":"Eur. J. Pediatr."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"Alpha-Glucosidase Deficiency in Generalized Glycogenstorage Disease (Pompe\u2019s Disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem. J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1471-4159.1963.tb11905.x","article-title":"A controlled study of enzymic activities in three human disorders of glycolipid metabolism","volume":"10","author":"Austin","year":"1963","journal-title":"J. Neurochem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"115346","DOI":"10.1016\/j.ab.2023.115346","article-title":"Two Fluorimetric Determinations of Acid \u03b1-Glucosidase Activity in Dried Blood Spot: Pompe Disease in Iranian Population","volume":"682","author":"Khatami","year":"2023","journal-title":"Anal. Biochem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/jhg.2017.36","article-title":"Successful Newborn Screening for Gaucher Disease Using Fluorometric Assay in China","volume":"62","author":"Kang","year":"2017","journal-title":"J. Hum. Genet."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ejmg.2015.10.014","article-title":"Enzymatic Diagnosis of Fabry Disease Using a Fluorometric Assay on Dried Blood Spots: An Alternative Methodology","volume":"58","author":"Caudron","year":"2015","journal-title":"Eur. J. Med. Genet."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Washburn, J., and Millington, D.S. (2020). Digital Microfluidics in Newborn Screening for Mucopolysaccharidoses: A Progress Report. Int. J. Neonatal Screen., 6.","DOI":"10.3390\/ijns6040078"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1021\/j150664a002","article-title":"Electrospray Ion Source. Another Variation on the Free-Jet Theme","volume":"88","author":"Yamashita","year":"1984","journal-title":"J. Phys. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2004.035907","article-title":"Direct Multiplex Assay of Lysosomal Enzymes in Dried Blood Spots for Newborn Screening","volume":"50","author":"Li","year":"2004","journal-title":"Clin. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1373\/clinchem.2012.189936","article-title":"High-Throughput Assay of 9 Lysosomal Enzymes for Newborn Screening","volume":"59","author":"Spacil","year":"2013","journal-title":"Clin. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1021\/acs.analchem.2c03098","article-title":"Development of a Universal Second-Tier Newborn Screening LC-MS\/MS Method for Amino Acids, Lysophosphatidylcholines, and Organic Acids","volume":"95","author":"Kilgore","year":"2023","journal-title":"Anal. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/s41436-020-0878-2","article-title":"The Multiple Faces of Urinary Glucose Tetrasaccharide as Biomarker for Patients with Hepatic Glycogen Storage Diseases","volume":"22","author":"Maatman","year":"2020","journal-title":"Genet. Med."},{"key":"ref_105","first-page":"191","article-title":"Very Low Arylsulfatase A and Cerebroside Sulfatase Activities in Leukocytes of Healthy Members of Metachromatic Leukodystrophy Family","volume":"29","author":"Dubois","year":"1977","journal-title":"Am. J. Hum. Genet."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"jcs221739","DOI":"10.1242\/jcs.221739","article-title":"Lysosomal Storage Disorders\u2014Challenges, Concepts and Avenues for Therapy: Beyond Rare Diseases","volume":"132","author":"Marques","year":"2019","journal-title":"J. Cell Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mas.20186","article-title":"Orbitrap Mass Spectrometry: Instrumentation, Ion Motion and Applications","volume":"27","author":"Perry","year":"2008","journal-title":"Mass Spectrom. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F","article-title":"High Sensitivity Collisionally-Activated Decomposition Tandem Mass Spectrometry on a Novel Quadrupole\/Orthogonal-Acceleration Time-of-Flight Mass Spectrometer","volume":"10","author":"Morris","year":"1996","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1007\/s13361-019-02288-2","article-title":"Ion Mobility Spectrometry: Fundamental Concepts, Instrumentation, Applications, and the Road Ahead","volume":"30","author":"Dodds","year":"2019","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ymgme.2021.08.006","article-title":"Detecting Lysosomal Storage Disorders by Glycomic Profiling Using Liquid Chromatography Mass Spectrometry","volume":"134","author":"Mak","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11306-023-01989-w","article-title":"Combined Targeted and Untargeted High-Resolution Mass Spectrometry Analyses to Investigate Metabolic Alterations in Pompe Disease","volume":"19","author":"Peake","year":"2023","journal-title":"Metabolomics"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"343824","DOI":"10.1016\/j.aca.2025.343824","article-title":"Profiling and Semi-Quantitation of Urine Sulfatides by UHPLC-Orbitrap-HRMS","volume":"1350","author":"Gerrits","year":"2025","journal-title":"Anal. Chim. Acta"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1515\/cclm-2019-0868","article-title":"Matrix-Assisted Laser Desorption Ionisation (MALDI) Mass Spectrometry (MS): Basics and Clinical Applications","volume":"58","author":"Israr","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1373\/clinchem.2012.201053","article-title":"Oligosaccharide Analysis in Urine by Maldi-Tof Mass Spectrometry for the Diagnosis of Lysosomal Storage Diseases","volume":"59","author":"Xia","year":"2013","journal-title":"Clin. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/252285a0","article-title":"Observation of Tissue Metabolites Using 31P Nuclear Magnetic Resonance","volume":"252","author":"Hoult","year":"1974","journal-title":"Nature"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"108809","DOI":"10.1016\/j.biotechadv.2026.108809","article-title":"Advances in NMR Spectroscopy for Biological Systems: Principles, Techniques, and Their Growing Scope","volume":"88","author":"Aboalroub","year":"2026","journal-title":"Biotechnol. Adv."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/2213235X02666141112215616","article-title":"1H NMR-Linked Urinary Metabolic Profiling of Niemann-Pick Class C1 (NPC1) Disease: Identification of Potential New Biomarkers Using Correlated Component Regression (CCR) and Genetic Algorithm (GA) Analysis Strategies","volume":"2","author":"Vruchte","year":"2014","journal-title":"Curr. Metabolomics"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-4939-9690-2_4","article-title":"High-Resolution Magic Angle Spinning (HRMAS) NMR Methods in Metabolomics","volume":"2037","author":"Tilgner","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00216-024-05137-8","article-title":"NMR Spectroscopy for Metabolomics in the Living System: Recent Progress and Future Challenges","volume":"416","author":"Peng","year":"2024","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnmrs.2017.01.001","article-title":"Beyond the Paradigm: Combining Mass Spectrometry and Nuclear Magnetic Resonance for Metabolomics","volume":"100","author":"Marshall","year":"2017","journal-title":"Prog. Nucl. Magn. Reson. Spectrosc."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/mrc.5350","article-title":"Multiplatform Untargeted Metabolomics","volume":"61","author":"Jeppesen","year":"2023","journal-title":"Magn. Reson. Chem."},{"key":"ref_122","first-page":"92","article-title":"Multivariate Analysis in Metabolomics","volume":"1","author":"Worley","year":"2013","journal-title":"Curr. Metabolomics"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Galal, A., Talal, M., and Moustafa, A. (2022). Applications of Machine Learning in Metabolomics: Disease Modeling and Classification. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.1017340"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s12010-025-05458-z","article-title":"Current Advancements in Untargeted Metabolomics Analysis and Testing Driven by Machine Learning: Prospects for Artificial Intelligence in Patient-Centric Healthcare Transformation","volume":"198","author":"Singh","year":"2026","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"jjaf020","DOI":"10.1093\/ecco-jcc\/jjaf020","article-title":"Machine learning and metabolomics identify biomarkers associated with the disease extent of ulcerative colitis","volume":"19","author":"Ge","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Temur, \u0130., \u00d6zsan, M., Temur, K.T., and \u00c7olak, A.B. (2026). Prediction of preterm and low birth weight risk using a physiology based artificial neural network integrating hematological, dental, and periodontal index markers: A cross sectional study based on machine learning. BMC Pregnancy Childbirth, 26.","DOI":"10.1186\/s12884-026-08955-z"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature14539","article-title":"Deep Learning","volume":"521","author":"LeCun","year":"2015","journal-title":"Nature"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"bbad244","DOI":"10.1093\/bib\/bbad244","article-title":"An integrated deep learning framework for the interpretation of untargeted metabolomics data","volume":"24","author":"Tian","year":"2023","journal-title":"Brief. Bioinform."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1038\/s41467-026-72149-6","article-title":"Structure-informed deep generation enables de novo metabolite annotation in untargeted metabolomics","volume":"17","author":"Wang","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1145\/3422622","article-title":"Generative adversarial networks","volume":"63","author":"Goodfellow","year":"2020","journal-title":"Commun. ACM"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"105916","DOI":"10.1016\/j.compbiomed.2022.105916","article-title":"Application of data augmentation techniques towards metabolomics","volume":"148","author":"Franco","year":"2022","journal-title":"Comput. Biol. Med."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/7\/480\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:54:16Z","timestamp":1783533256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/7\/480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":131,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["metabo16070480"],"URL":"https:\/\/doi.org\/10.3390\/metabo16070480","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}